Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks. For maintenance, 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally twice daily, may be increased to a maximum of 240 mg orally daily in divided doses.
* **Intravenous (IV) administration:** Typically 40 mg IV once daily for patients unable to take oral medication.
## Pediatric Dosing
Dosing in pediatric patients is highly variable and depends on age, weight, and indication.
* **GERD/Erosive esophagitis (1-5 years):** 10 mg orally once daily for up to 8 weeks.
* **GERD/Erosive esophagitis (5-16 years):** 20 mg orally once daily for up to 8 weeks.
* **IV administration (12-16 years):** 40 mg IV once daily.
*Note: Dosing in children can vary significantly based on specific guidelines and clinical judgment. Always refer to specific pediatric protocols.*
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness.
Long-term use of PPIs may be associated with:
* Increased risk of *Clostridium difficile*-associated diarrhea.
* Bone fractures (hip, wrist, spine).
* Hypomagnesemia.
* Vitamin B12 deficiency.
* Rebound acid hypersecretion upon discontinuation.
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternative PPIs or avoidance if possible, especially in high-risk patients.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Monitor methotrexate levels and consider dose adjustment or temporary discontinuation of pantoprazole.
* **Drugs dependent on gastric pH for absorption:** May affect absorption (e.g., ketoconazole, itraconazole, atazanavir, nelfinavir).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, muscle spasms, seizures, arrhythmias) with prolonged use.
* Monitor for signs and symptoms of *C. difficile* infection.
* Consider monitoring magnesium levels periodically, especially in patients on long-term therapy or taking concomitant medications that may lower magnesium (e.g., diuretics).
## Clinical Pearls
* Pantoprazole is generally considered less likely to interact with clopidogrel compared to omeprazole or esomeprazole, but caution is still advised.
* Oral formulations should be swallowed whole and not chewed or crushed.
* IV formulation should be reconstituted and further diluted before administration.
* Discontinuation should be considered gradually to minimize the risk of rebound acid hypersecretion.
***
*This information is intended for clinical use and does not replace the need to consult the official prescribing information and relevant clinical guidelines. Always verify current prescribing information before making clinical decisions.*
